Kairos Pharma, LTD. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Kairos Pharma performed this year. My goal is to cut through the corporate jargon so you can decide if this company is a good fit for your portfolio.

1. What does this company do?

Kairos Pharma is a clinical-stage biotech company focused on researching and developing new cancer treatments. They do not have products on pharmacy shelves yet; instead, they are focused on the long, expensive process of clinical trials and securing patents.

They are working on seven drug candidates to fight drug resistance in prostate, lung, and brain cancers. Their "Selective Targeting and Inhibition of Proteins" (STIP) platform aims to stop cancer cells from dodging chemotherapy and immunotherapy.

2. How did they perform this year?

This year was a major transition. The company began trading on the NYSE American (ticker: KAPA) on February 15, 2024, after merging with a special purpose acquisition company.

Operationally, they focus on "unlocking" cancer cells that resist standard treatments. Their lead drug, ENV 105, is in a Phase 2 trial for prostate cancer. In a recent study, 62% of patients saw their disease stabilize or shrink. While this is promising, these trials are still ongoing with small groups. The company is now working to expand enrollment to meet the standards required for FDA approval.

3. Financial health: The "Burn Rate"

Because Kairos is still in the research phase, they generated $0 in sales for the year ending December 31, 2023. They currently spend $600,000 to $800,000 per month to fund their labs and trials.

They use a "virtual" model, meaning they outsource clinical trials to third parties to keep costs low. However, they rely entirely on selling shares or warrants to investors to keep the lights on. They reported about $4.2 million in cash. This is a high-stakes biotech model: they must keep raising money to survive until their drugs are proven. If they cannot raise more capital, their research will likely stop within 6 to 9 months.

4. Major wins and hurdles

• The Big Win: They have a diverse pipeline of seven drugs. They also received a $3.2 million grant from the National Institutes of Health (NIH) for ENV 105. This is a major vote of confidence from outside experts and provides cash without issuing more shares.
• The Hurdle: The "cash runway." Because they have no income, they must frequently raise capital. This often leads to more shares being issued, which reduces your ownership percentage and can lower the value of your existing shares.

5. Key risks

• Clinical Trial Failure: This is the biggest risk. If their drugs fail in larger trials, the company’s value could drop significantly.
• Regulatory Hurdles: They are at the mercy of the FDA. There is no guarantee their drugs will be approved. The FDA may demand more costly trials if current data isn't enough.
• Competition: They face stiff competition. They must prove their treatments are better than those from massive pharmaceutical companies with much larger budgets.

Final Thought for Investors: This is a high-risk, speculative investment. You are betting on the success of scientific research, not current profits. Before deciding to invest, ask yourself if you are comfortable with the high volatility and the potential for further share dilution that comes with a company in this stage of development.